Verrica Pharmaceuticals Stock Forecast, Price & News

Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions

Is Verrica Pharmaceuticals a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Verrica Pharmaceuticals stock.
View analyst ratings for Verrica Pharmaceuticals or view top-rated stocks.

How has Verrica Pharmaceuticals' stock price been impacted by COVID-19?

Verrica Pharmaceuticals' stock was trading at $10.52 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VRCA shares have decreased by 12.0% and is now trading at $9.26.
View which stocks have been most impacted by COVID-19.

When is Verrica Pharmaceuticals' next earnings date?

Verrica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Verrica Pharmaceuticals.

How were Verrica Pharmaceuticals' earnings last quarter?

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released its quarterly earnings data on Friday, November, 12th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.04.
View Verrica Pharmaceuticals' earnings history.

What price target have analysts set for VRCA?

5 analysts have issued 12-month target prices for Verrica Pharmaceuticals' stock. Their forecasts range from $16.00 to $20.00. On average, they anticipate Verrica Pharmaceuticals' stock price to reach $18.80 in the next year. This suggests a possible upside of 103.0% from the stock's current price.
View analysts' price targets for Verrica Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Verrica Pharmaceuticals' key executives?

Verrica Pharmaceuticals' management team includes the following people:

• Ted White, President, Chief Executive Officer & Director (LinkedIn Profile)
• Terry Kohler, Chief Financial & Accounting Officer
• Gary Goldenberg, Chief Medical Officer
• Eugene Scavola, Executive Vice President-Technical Operations
• Christopher G. Hayes, Secretary, Chief Legal & Compliance Officer (LinkedIn Profile)

Who are some of Verrica Pharmaceuticals' key competitors?

Some companies that are related to Verrica Pharmaceuticals include PMV Pharmaceuticals (PMVP), CannTrust (CNTTF), MacroGenics (MGNX), Seres Therapeutics (MCRB), Amphastar Pharmaceuticals (AMPH), Arcturus Therapeutics (ARCT), GH Research (GHRS), Nuvalent (NUVL), Merus (MRUS), Zealand Pharma A/S (ZEAL), Vanda Pharmaceuticals (VNDA), RAPT Therapeutics (RAPT), Heron Therapeutics (HRTX), Tango Therapeutics (TNGX) and BELLUS Health (BLUSF).
View all of VRCA's competitors.

What other stocks do shareholders of Verrica Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Novan (NOVN), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), OrganiGram (OGI) and Aeterna Zentaris (AEZS).

When did Verrica Pharmaceuticals IPO?

(VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen acted as the underwriters for the IPO.

What is Verrica Pharmaceuticals' stock symbol?

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Who are Verrica Pharmaceuticals' major shareholders?

Verrica Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.35%), Altium Capital Management LP (0.93%), Geode Capital Management LLC (0.87%), Bank of New York Mellon Corp (0.16%), MML Investors Services LLC (0.16%) and Morgan Stanley (0.16%). Company insiders that own Verrica Pharmaceuticals stock include A Brian Davis, Christopher G Hayes, Craig Ballaron, Paul B Manning and Ted White.
View institutional ownership trends for Verrica Pharmaceuticals.

Which institutional investors are selling Verrica Pharmaceuticals stock?

VRCA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Altium Capital Management LP, Morgan Stanley, BlackRock Inc., California State Teachers Retirement System, and UBS Group AG.
View insider buying and selling activity for Verrica Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Verrica Pharmaceuticals stock?

VRCA stock was acquired by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, HighVista Strategies LLC, MML Investors Services LLC, Citadel Advisors LLC, Barclays PLC, Bank of New York Mellon Corp, and BNP Paribas Arbitrage SA. Company insiders that have bought Verrica Pharmaceuticals stock in the last two years include A Brian Davis, Christopher G Hayes, Craig Ballaron, Paul B Manning, and Ted White.
View insider buying and selling activity for Verrica Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Verrica Pharmaceuticals?

Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verrica Pharmaceuticals' stock price today?

One share of VRCA stock can currently be purchased for approximately $9.26.

How much money does Verrica Pharmaceuticals make?

Verrica Pharmaceuticals has a market capitalization of $254.83 million. The company earns $-42.69 million in net income (profit) each year or ($1.41) on an earnings per share basis.

How many employees does Verrica Pharmaceuticals have?

Verrica Pharmaceuticals employs 29 workers across the globe.

What is Verrica Pharmaceuticals' official website?

The official website for Verrica Pharmaceuticals is www.verrica.com.

Where are Verrica Pharmaceuticals' headquarters?

Verrica Pharmaceuticals is headquartered at 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380.

How can I contact Verrica Pharmaceuticals?

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at (434) 453-3300 or via email at [email protected].